Cargando…

Secondary antibody deficiency: a complication of anti-CD20 therapy for neuroinflammation

B-cell depleting anti-CD20 monoclonal antibody therapies are being increasingly used as long-term maintenance therapy for neuroinflammatory disease compared to many non-neurological diseases where they are used as remission-inducing agents. While hypogammaglobulinaemia is known to occur in over half...

Descripción completa

Detalles Bibliográficos
Autores principales: Tallantyre, E. C., Whittam, D. H., Jolles, S., Paling, D., Constantinesecu, C., Robertson, N. P., Jacob, A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5937879/
https://www.ncbi.nlm.nih.gov/pubmed/29511864
http://dx.doi.org/10.1007/s00415-018-8812-0
_version_ 1783320698463191040
author Tallantyre, E. C.
Whittam, D. H.
Jolles, S.
Paling, D.
Constantinesecu, C.
Robertson, N. P.
Jacob, A.
author_facet Tallantyre, E. C.
Whittam, D. H.
Jolles, S.
Paling, D.
Constantinesecu, C.
Robertson, N. P.
Jacob, A.
author_sort Tallantyre, E. C.
collection PubMed
description B-cell depleting anti-CD20 monoclonal antibody therapies are being increasingly used as long-term maintenance therapy for neuroinflammatory disease compared to many non-neurological diseases where they are used as remission-inducing agents. While hypogammaglobulinaemia is known to occur in over half of patients treated with medium to long-term B-cell-depleting therapy (in our cohort IgG 38, IgM 56 and IgA 18%), the risk of infections it poses seems to be under-recognised. Here, we report five cases of serious infections associated with hypogammaglobulinaemia occurring in patients receiving rituximab for neuromyelitis optica spectrum disorders. Sixty-four per cent of the whole cohort of patients studied had hypogammaglobulinemia. We discuss the implications of these cases to the wider use of anti-CD20 therapy in neuroinflammatory disease.
format Online
Article
Text
id pubmed-5937879
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-59378792018-05-11 Secondary antibody deficiency: a complication of anti-CD20 therapy for neuroinflammation Tallantyre, E. C. Whittam, D. H. Jolles, S. Paling, D. Constantinesecu, C. Robertson, N. P. Jacob, A. J Neurol Original Communication B-cell depleting anti-CD20 monoclonal antibody therapies are being increasingly used as long-term maintenance therapy for neuroinflammatory disease compared to many non-neurological diseases where they are used as remission-inducing agents. While hypogammaglobulinaemia is known to occur in over half of patients treated with medium to long-term B-cell-depleting therapy (in our cohort IgG 38, IgM 56 and IgA 18%), the risk of infections it poses seems to be under-recognised. Here, we report five cases of serious infections associated with hypogammaglobulinaemia occurring in patients receiving rituximab for neuromyelitis optica spectrum disorders. Sixty-four per cent of the whole cohort of patients studied had hypogammaglobulinemia. We discuss the implications of these cases to the wider use of anti-CD20 therapy in neuroinflammatory disease. Springer Berlin Heidelberg 2018-03-06 2018 /pmc/articles/PMC5937879/ /pubmed/29511864 http://dx.doi.org/10.1007/s00415-018-8812-0 Text en © The Author(s) 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Communication
Tallantyre, E. C.
Whittam, D. H.
Jolles, S.
Paling, D.
Constantinesecu, C.
Robertson, N. P.
Jacob, A.
Secondary antibody deficiency: a complication of anti-CD20 therapy for neuroinflammation
title Secondary antibody deficiency: a complication of anti-CD20 therapy for neuroinflammation
title_full Secondary antibody deficiency: a complication of anti-CD20 therapy for neuroinflammation
title_fullStr Secondary antibody deficiency: a complication of anti-CD20 therapy for neuroinflammation
title_full_unstemmed Secondary antibody deficiency: a complication of anti-CD20 therapy for neuroinflammation
title_short Secondary antibody deficiency: a complication of anti-CD20 therapy for neuroinflammation
title_sort secondary antibody deficiency: a complication of anti-cd20 therapy for neuroinflammation
topic Original Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5937879/
https://www.ncbi.nlm.nih.gov/pubmed/29511864
http://dx.doi.org/10.1007/s00415-018-8812-0
work_keys_str_mv AT tallantyreec secondaryantibodydeficiencyacomplicationofanticd20therapyforneuroinflammation
AT whittamdh secondaryantibodydeficiencyacomplicationofanticd20therapyforneuroinflammation
AT jolless secondaryantibodydeficiencyacomplicationofanticd20therapyforneuroinflammation
AT palingd secondaryantibodydeficiencyacomplicationofanticd20therapyforneuroinflammation
AT constantinesecuc secondaryantibodydeficiencyacomplicationofanticd20therapyforneuroinflammation
AT robertsonnp secondaryantibodydeficiencyacomplicationofanticd20therapyforneuroinflammation
AT jacoba secondaryantibodydeficiencyacomplicationofanticd20therapyforneuroinflammation